NCT04009291 - A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 27, 2019

Primary Completion Date

March 6, 2020

Study Completion Date

April 17, 2025

Conditions

HypoparathyroidismEndocrine System DiseasesParathyroid Diseases

Interventions

COMBINATION_PRODUCT

TransCon PTH

TransCon PTH drug product is supplied as a clear solution containing TransCon PTH with a nominal PTH(1-34) content of 0.3 mg/mL in a pre-filled pen intended for subcutaneous injection.

COMBINATION_PRODUCT

Placebo for TransCon PTH

Placebo is supplied as a clear solution containing the formulation buffer for TransCon PTH in a pre-filled pen intended for subcutaneous injection.

Trial Locations (15)

2200

Ascendis Pharma Investigational Site, Copenhagen

8200

Ascendis Pharma Investigational Site, Aarhus

9000

Ascendis Pharma Investigational Site, Aalborg

10032

Ascendis Pharma Investigational Site, New York

11021

Ascendis Pharma Investigational Site, Great Neck

19104

Ascendis Pharma Investigational Site, Philadelphia

20132

Ascendis Pharma Investigational Site, Milan

40138

Ascendis Pharma Investigational Site, Bologna

55901

Ascendis Pharma Investigational Site, Rochester

56124

Ascendis Pharma Investigational Site, Pisa

60637

Ascendis Pharma Investigational Site, Chicago

L6M 1M1

Ascendis Pharma Investigational Site, Oakville

01307

Ascendis Pharma Investigational Site, Dresden

00128

Ascendis Pharma Investigational Site, Rome

0176

Ascendis Pharma Investigational Site, Oslo